TX-FLUENCE
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its success in supporting Trichome, an Israeli facility growing world-class medicinal cannabis, to prove the concept of two-tiered vertical farming in an urban center.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230510005315/en/
Fluence LEDs inside Trichome's urban facility have supported 17 full crop growing cycles, all with greater than expected results. (Photo: Business Wire)
To successfully launch an urban vertical growing facility in Qiryat Gat, Israel, Trichome needed to collaborate with the right solution partners to maximize space while optimizing quality and automation at every step of the process. To appropriately design for the compact, intricate indoor environment and complexities associated with tiered growing, Trichome turned to Fluence for its market-leading LED lighting solutions, local service capabilities through Fluence's Israeli distribution partner, REMY, and in-house horticultural experts to assist with planning, installing and managing the deployment of integrated lighting technology.
“By partnering with Fluence, we were not reinventing the wheel but choosing the best wheels in the market,” said Tony Levi, co-founder and CEO of Trichome. “Standardization, longevity and optimization are critical factors in producing high-quality cannabis flowers. The team of experts at Fluence helped us accomplish all of those goals in an urban farm within city limits.”
Trichome installed Fluence lighting throughout its fully standardized medicinal cannabis facility. To overcome the obstacles presented by a reduction in space between crops and the artificial lights in vertical farms, Fluence worked closely with REMY, Levi and the Trichome team to understand the facility’s constraints. Ultimately, Fluence designed a bespoke system comprising its SPYDR 2i, SPYDR 2x and RAZR Modular series for Trichome. Trichome has completed 17 full crop growing cycles, all with greater than expected results using Fluence lighting—including above average yields, higher than expected terpene levels and high cannabinoid content.
“We are thrilled by the response of our plants to the Fluence LED lighting,” said Steve Abboud, head grower at Trichome. “Our cannabis crops are taking in the light from Fluence fixtures and expressing its quality through their flowering. We have been able to standardize light intensity, harness control over our cultivation methods and achieve crop uniformity because of Fluence LEDs.”
“Working with Trichome on lighting solutions has been an exciting and ambitious process where both parties learned a tremendous amount,” said Jörg Meyer-Brenken, lead account manager, cannabis EMEA at Fluence. “The product Trichome supplies is outstanding, but the feedback from the market and patients makes me even prouder. Trichome has been able to set a new bar for urban farming.”
Fluence LED lighting solutions are available for purchase by licensed cultivators in territories in which the cultivation of cannabis is legal.
For more information on Fluence, visit www.fluence.science.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
About REMY
Established in 2008, REMY 108 LTD specializes in the planning, installation, integration and quality assurance of large-scale agronomic lighting solutions, as well as after-sales service and support, for commercial crop and food cultivation in Israel and beyond. REMY has been providing its customers with agronomic lighting since 2011 and has been the company’s main focus since 2018. An authorized reseller of Fluence LED lighting solutions, today, it also provides agronomic lighting training at its headquarters in Yanuv. For more information about REMY, visit https://www.remy.co.il/en/grow.
About Trichome
Trichome is an Israeli agritech company that combines two complementary worlds—quality cannabis agriculture and advanced cannabis technologies. The company philosophy is based on three main pillars: Indoor Growth by Advanced Technology, an international team of cannabis experts and the finest, high-end varieties. Trichome owns the largest Indoor facility for medical cannabis cultivation in the Middle East. With nine flowering rooms, the multilayer facility is spread over 7,000 square meters and has an annual production capacity of six tons of high-quality, consistent standardized inflorescence. Trichome works through several channels including its own brand and white label. For more information, visit www.trichome-il.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230510005315/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom